ETON PHARMACEUTICALS INC (ETON)

US29772L1089 - Common Stock

12.57  +0.29 (+2.36%)

After market: 12.57 0 (0%)

Fundamental Rating

4

ETON gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. While ETON seems to be doing ok healthwise, there are quite some concerns on its profitability. ETON is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

ETON had negative earnings in the past year.
ETON had a positive operating cash flow in the past year.
ETON had negative earnings in each of the past 5 years.
In multiple years ETON reported negative operating cash flow during the last 5 years.

1.2 Ratios

ETON has a better Return On Assets (-15.29%) than 65.79% of its industry peers.
ETON has a better Return On Equity (-34.30%) than 65.26% of its industry peers.
Industry RankSector Rank
ROA -15.29%
ROE -34.3%
ROIC N/A
ROA(3y)-15.37%
ROA(5y)-51.94%
ROE(3y)-28.71%
ROE(5y)-87.68%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

ETON's Gross Margin of 59.30% is fine compared to the rest of the industry. ETON outperforms 66.84% of its industry peers.
ETON does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 59.3%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

6

2. Health

2.1 Basic Checks

ETON does not have a ROIC to compare to the WACC, probably because it is not profitable.
ETON has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ETON has more shares outstanding
Compared to 1 year ago, ETON has an improved debt to assets ratio.

2.2 Solvency

An Altman-Z score of 6.74 indicates that ETON is not in any danger for bankruptcy at the moment.
ETON has a better Altman-Z score (6.74) than 84.21% of its industry peers.
ETON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.74
ROIC/WACCN/A
WACC9.92%

2.3 Liquidity

A Current Ratio of 1.51 indicates that ETON should not have too much problems paying its short term obligations.
The Current ratio of ETON (1.51) is worse than 72.63% of its industry peers.
A Quick Ratio of 1.41 indicates that ETON should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.41, ETON is not doing good in the industry: 67.89% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.51
Quick Ratio 1.41

More info and screens

6

3. Growth

3.1 Past

ETON shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -400.00%.
Looking at the last year, ETON shows a small growth in Revenue. The Revenue has grown by 5.63% in the last year.
ETON shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 824.84% yearly.
EPS 1Y (TTM)-400%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%250%
Revenue 1Y (TTM)5.63%
Revenue growth 3Y824.84%
Revenue growth 5YN/A
Sales Q2Q%46.9%

3.2 Future

The Earnings Per Share is expected to grow by 95.91% on average over the next years. This is a very strong growth
ETON is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 39.30% yearly.
EPS Next Y-129.5%
EPS Next 2Y202.32%
EPS Next 3Y150.77%
EPS Next 5Y95.91%
Revenue Next Year18.51%
Revenue Next 2Y46.16%
Revenue Next 3Y44.92%
Revenue Next 5Y39.3%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ETON reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
ETON is valuated quite expensively with a Price/Forward Earnings ratio of 29.34.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ETON indicates a somewhat cheap valuation: ETON is cheaper than 77.37% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of ETON to the average of the S&P500 Index (23.73), we can say ETON is valued slightly more expensively.
Industry RankSector Rank
PE N/A
Fwd PE 29.34

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as ETON's earnings are expected to grow with 150.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y202.32%
EPS Next 3Y150.77%

More info and screens

0

5. Dividend

5.1 Amount

ETON does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ETON PHARMACEUTICALS INC

NASDAQ:ETON (12/20/2024, 8:07:41 PM)

After market: 12.57 0 (0%)

12.57

+0.29 (+2.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners33.16%
Inst Owner Change15.71%
Ins Owners5.39%
Ins Owner Change0%
Market Cap334.74M
Analysts82.5
Price Target15.3 (21.72%)
Short Float %1.12%
Short Ratio1.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)163.03%
Min EPS beat(2)-68.07%
Max EPS beat(2)394.12%
EPS beat(4)2
Avg EPS beat(4)60.03%
Min EPS beat(4)-120.59%
Max EPS beat(4)394.12%
EPS beat(8)6
Avg EPS beat(8)113.25%
EPS beat(12)7
Avg EPS beat(12)32.9%
EPS beat(16)8
Avg EPS beat(16)20.49%
Revenue beat(2)2
Avg Revenue beat(2)2.75%
Min Revenue beat(2)1.09%
Max Revenue beat(2)4.4%
Revenue beat(4)2
Avg Revenue beat(4)-0.94%
Min Revenue beat(4)-6.89%
Max Revenue beat(4)4.4%
Revenue beat(8)5
Avg Revenue beat(8)11.57%
Revenue beat(12)6
Avg Revenue beat(12)-2.77%
Revenue beat(16)6
Avg Revenue beat(16)-14.15%
PT rev (1m)15.38%
PT rev (3m)87.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-200%
EPS NY rev (1m)22.86%
EPS NY rev (3m)10%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.23%
Revenue NY rev (1m)2.2%
Revenue NY rev (3m)2.2%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 29.34
P/S 9.65
P/FCF N/A
P/OCF 157.97
P/B 20.95
P/tB 33.05
EV/EBITDA N/A
EPS(TTM)-0.21
EYN/A
EPS(NY)0.43
Fwd EY3.41%
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)0.08
OCFY0.63%
SpS1.3
BVpS0.6
TBVpS0.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.29%
ROE -34.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 59.3%
FCFM N/A
ROA(3y)-15.37%
ROA(5y)-51.94%
ROE(3y)-28.71%
ROE(5y)-87.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.97
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 250.19%
Cap/Sales 7.66%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.51
Quick Ratio 1.41
Altman-Z 6.74
F-Score3
WACC9.92%
ROIC/WACCN/A
Cap/Depr(3y)317.45%
Cap/Depr(5y)274.23%
Cap/Sales(3y)10.17%
Cap/Sales(5y)69.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-400%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%250%
EPS Next Y-129.5%
EPS Next 2Y202.32%
EPS Next 3Y150.77%
EPS Next 5Y95.91%
Revenue 1Y (TTM)5.63%
Revenue growth 3Y824.84%
Revenue growth 5YN/A
Sales Q2Q%46.9%
Revenue Next Year18.51%
Revenue Next 2Y46.16%
Revenue Next 3Y44.92%
Revenue Next 5Y39.3%
EBIT growth 1Y-259.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year47.22%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y94.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y167.48%
OCF growth 3YN/A
OCF growth 5YN/A